Clinical stage biotech company Phanes Therapeutics, Inc. (Phanes) announced on Monday that it has dosed its first subject in a clinical study of PT886 in combination with chemotherapy.

The study has completed dosing in two cohorts, one for first-line treatment of pancreatic cancers and another for second-line treatment of gastric, gastroesophageal junction cancers.

The product, a first-in-class native IgG-like bispecific antibody (bsAb), is aimed at claudin 18.2 and CD47. It received orphan drug designation (ODD) for the treatment of pancreatic cancer by the FDA in 2022 and was offered Fast Track designation for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma earlier this year.

The multi-centre Phase I/II clinical trial of PT886 (NCT05482893) called the TWINPEAK study, is currently assessing the product in patients with locally advanced or metastatic gastric, gastroesophageal junction and pancreatic cancers that have progressed after all available standard therapy or for which standard therapy has proven to be ineffective, intolerable, or is considered inappropriate. The company is conducting a Phase one clinical trial of the product in China (CTR20241655).